Dr Michael Schachter

Publications


Journals

  • Schachter M. (2 Apr 2012). THE UNRAVELLING NHS Instead of jumping up and down we must propose alternatives. BRITISH MEDICAL JOURNAL. 344. Author weblink DOI.
  • Schachter M. (2012). Instead of jumping up and down we must propose alternatives. BMJ. 344:e2442.
  • Schachter M. (14 Feb 2012). MANAGING HYPERTENSION Professional judgment is key in treating hypertension. BRITISH MEDICAL JOURNAL. 344. Author weblink DOI.
  • Schachter M. (2012). Professional judgment is key in treating hypertension. BMJ. 344:e1033.
  • Schachter M. (1 Nov 2011). A SUNSHINE ACT FOR EUROPE Spare me the English middle class's snobbery about trade. BRITISH MEDICAL JOURNAL. 343. Author weblink DOI.
  • Schachter M. (2011). Spare me the English middle class's snobbery about trade. BMJ. 343:d7026.
  • Franklin BD; Birch S; Schachter M; Barber N. (Oct 2010). Testing a trigger tool as a method of detecting harm from medication errors in a UK hospital: a pilot study. Int J Pharm Pract. 18:305-311. DOI.
  • Chapman N; Schachter M. (Feb 2010). Clopidogrel and calcium-channel blockers: a clinically important interaction?. Heart. 96:179-180. DOI.
  • Schachter M. (1 Sep 2009). Professionalism, again. MEDICAL EDUCATION. 43:925-925. Author weblink DOI.
  • Schachter M. (29 Jun 2009). Drug prevention of hypertension Up to a point. BRITISH MEDICAL JOURNAL. 339. Author weblink DOI.
  • Schachter M. (Jun 2009). The epidemiology of medication errors: how many, how serious?. Br J Clin Pharmacol. 67:621-623. DOI.
  • Cohen AF; Loke YK; Lewis LD; Schachter M; Somogyi A; Ritter JM. (1 Feb 2009). Editors' Report, December 2008. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 67:151-152. Author weblink DOI.
  • Honarbakhsh S; Schachter M. (Apr 2009). Vitamins and cardiovascular disease. Br J Nutr. 101:1113-1131. DOI.
  • Schachter M. (1 Feb 2007). Manet and Maximilian (The article on Manet's painting of the execution of the Emperor Maximilian). HISTORY TODAY. 57:67-67. Author weblink.
  • Schachter M; Wierzbicki AS. (20 May 2006). Spinning stars: ASTEROID's impact on atherosclerosis. LANCET. 367:1655-1656. Author weblink DOI.
  • Schachter M. (Dec 2005). Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Cardiovasc Drugs Ther. 19:415-422. DOI.
  • Schachter M. (1 Sep 2005). Changes in the usage of antihypertensive drugs: implications and prospects. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 60:231-234. Author weblink DOI.
  • Mikhailidis DP; Wierzbicki AS; Daskalopoulou SS; Al-Saady N; Griffiths H; Hamilton G; Monkman D; Patel V; et alPittard J; Schachter M. (1 Jun 2005). The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. CURRENT MEDICAL RESEARCH AND OPINION. 21:959-969. Author weblink DOI.
  • Schachter M. (Apr 2005). Cardiac valvulopathy. Hosp Med. 66:228.
  • Schachter M. (Feb 2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 19:117-125. DOI.
  • Dean Franklin B; Vincent C; Schachter M; Barber N. (2005). The incidence of prescribing errors in hospital inpatients: an overview of the research methods. Drug Saf. 28:891-900.
  • Schachter M. (2005). Uric acid and hypertension. Curr Pharm Des. 11:4139-4143.
  • Schachter M; Mitchell G; Niziol C; Abhyankar BA. (Jul 2003). Antihypertensive efficacy of moxonidine in primary care: a 'real-life' study. Int J Clin Pract. 57:479-482.
  • Dean B; Schachter M; Vincent C; Barber N. (Dec 2002). Prescribing errors in hospital inpatients: their incidence and clinical significance. Qual Saf Health Care. 11:340-344.
  • Schachter M. (Jul 2002). Managing dyslipidaemia: current concepts. Practitioner. 246:496-499.
  • Valabhji J; Donovan J; McColl AJ; Schachter M; Richmond W; Elkeles RS. (May 2002). Rates of cholesterol esterification and esterified cholesterol net mass transfer between high-density lipoproteins and apolipoprotein B-containing lipoproteins in Type 1 diabetes. Diabet Med. 19:424-428.
  • Dean B; Schachter M; Vincent C; Barber N. (20 Apr 2002). Causes of prescribing errors in hospital inpatients: a prospective study. Lancet. 359:1373-1378. DOI.
  • Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS. (Dec 2001). High-density lipoprotein composition and paraoxonase activity in Type I diabetes. Clin Sci (Lond). 101:659-670.
  • Valabhji J; McColl AJ; Richmond W; Schachter M; Rubens MB; Elkeles RS. (Sep 2001). Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care. 24:1608-1613.
  • Unlu S; Clunn G; Schachter M; Demoliou-Mason C; Hughes AD. (Aug 2001). Action of an HMG CoA reductase inhibitor, lovastatin, on apoptosis of untransformed and ts-SV40 transformed human smooth muscle cells derived from saphenous vein. J Cardiovasc Pharmacol. 38:161-173.
  • Valabhji J; Donovan J; Kyd PA; Schachter M; Elkeles RS. (Jun 2001). The relationship between active renin concentration and plasma renin activity in Type 1 diabetes. Diabet Med. 18:451-458.
  • Robinson S; Valabhji J; Schachter M. (24 Feb 2001). The failings of NICE - NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal. BRITISH MEDICAL JOURNAL. 322:491-491. Author weblink.
  • Foulds S; Galustian C; Mansfield AO; Schachter M. (Jan 2001). Transcription factor NF kappa B expression and postsurgical organ dysfunction. Ann Surg. 233:70-78.
  • Clunn G; Hughes A; Schachter M. (16 Dec 2000). Endotoxin-lipoprotein hypothesis. Lancet. 356:2097-2098. DOI.
  • Dean B; Barber N; Schachter M. (Dec 2000). What is a prescribing error?. Qual Health Care. 9:232-237.
  • Valabhji J; McColl AJ; Richmond W; Schachter M; Rubens M; Elkeles RS. (1 Aug 2000). Total antioxidant status and coronary heart disease in type 1 diabetes. DIABETOLOGIA. 43:A264-A264. Author weblink.
  • Schachter M. (31 Jul 2000). Lipoprotein (a) and cardiovascular risk. Int J Cardiol. 74:169-170.
  • Hsieh JK; Kletsas D; Clunn G; Hughes AD; Schachter M; Demoliou-Mason C. (Apr 2000). p53, p21(WAF1/CIP1), and MDM2 involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 20:973-981.
  • Hsieh JK; Kletsas D; Clunn G; Hughes AD; Schachter M; Demoliou-Mason C. (Mar 2000). p53, p21(WAF1/CIP1), and MDM2 involvement in proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 20:636-644.
  • Unlu S; Mason CD; Schachter M; Hughes AD. (Feb 2000). Perillyl alcohol, an inhibitor of geranylgeranyl transferase, induces apoptosis of immortalized human vascular smooth muscle cells in vitro. J Cardiovasc Pharmacol. 35:341-344.
  • Schachter M. (1 Jan 2000). Erectile dysfunction and lipid disorders. CURRENT MEDICAL RESEARCH AND OPINION. 16:S9-S12. Author weblink DOI.
  • Schachter M. (2000). Erectile dysfunction and lipid disorders. Curr Med Res Opin. 16 Suppl 1:s9-12.
  • Schachter M. (Nov 1999). Metabolic effects of moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab. 1:317-322.
  • Ibrahim J; Schachter M; Hughes AD; Sever PS. (Aug 1999). Low dose indapamide plus perindopril combination effects on cardiovascular structure and function in genetic hypertension. Clin Exp Pharmacol Physiol. 26:622-627.
  • Schachter M. (Aug 1999). Moxonidine: a review of safety and tolerability after seven years of clinical experience. J Hypertens Suppl. 17:S37-S39.
  • Patel MK; Refson JS; Schachter M; Hughes AD. (May 1999). Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis. Br J Pharmacol. 127:361-368. DOI.
  • Pickkers P; Garcha RS; Schachter M; Smits P; Hughes AD. (1 Apr 1999). Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. HYPERTENSION. 33:1043-1048. Author weblink.
  • Unlu S; Mason CD; Schachter M; Hughes AD. (Nov 1998). Interactions between HMG-CoA reductase inhibition and UVB irradiation on proliferation and apoptosis in SM1 smooth muscle cells. Biochem Soc Trans. 26:S322.
  • Patel MK; Refson JS; Schachter M; Hughes AD. (1 Oct 1998). Characterisation of [H-3]-heparin binding in human vascular smooth muscle cells. HYPERTENSION. 32:805-805. Author weblink.
  • Schachter M; Luszick J; Jäger B; Verboom C; Söhlke E. (Sep 1998). Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf. 19:191-203.
  • Refson JS; Schachter M; Patel MK; Hughes AD; Munro E; Chan P; Wolfe JH; Sever PS. (30 Jun 1998). Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells. Circulation. 97:2506-2510.
  • Schachter M. (Apr 1998). Centrally acting antihypertensives: not obsolete after all. Int J Clin Pract. 52:192-195.
  • Schachter M. (31 Dec 1997). Calcium antagonists and atherosclerosis. Int J Cardiol. 62 Suppl 2:S9-15.
  • Schachter M. (31 Dec 1997). The pathogenesis of atherosclerosis. Int J Cardiol. 62 Suppl 2:S3-S7.
  • Schachter M. (31 Dec 1997). Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers. INTERNATIONAL JOURNAL OF CARDIOLOGY. 62:S85-S90. Author weblink DOI.
  • Unlu S; Demoliou-Mason C; Schachter M; Hughes AD. (1 Dec 1997). Action of lovastatin on cell death in cultured SV-40 transformed human vascular smooth muscle cells. BRITISH JOURNAL OF PHARMACOLOGY. 122:U106-U106. Author weblink.
  • Sawhney N; Patel MK; Schachter M; Hughes AD. (Sep 1997). Inhibition of proliferation by heparin and expression of p53 in cultured human vascular smooth muscle cells. J Hum Hypertens. 11:611-614.
  • Clunn GF; Lymn JS; Schachter M; Hughes AD. (Aug 1997). Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells. Br J Pharmacol. 121:1789-1795. DOI.
  • Foulds S; Cheshire NJ; Schachter M; Wolfe JH; Mansfield AO. (Feb 1997). Endotoxin related early neutrophil activation is associated with outcome after thoracoabdominal aortic aneurysm repair. Br J Surg. 84:172-177.
  • Bdesha AS; Schachter M; Sever P; Witherow RO. (Dec 1996). Radioligand-binding analysis of human prostatic alpha-1 adrenoreceptor density following transurethral microwave therapy. Br J Urol. 78:886-892.
  • Schachter M; Sawhney N; Refson JS; Hughes AD; Sever PS. (1 Oct 1996). Thrombospondin and growth regulation in human vascular smooth muscle cells. HYPERTENSION. 28:704-704.
  • Ibrahim J; Hughes AD; Schachter M; Sever PS. (Aug 1996). Depletion of resistance vessel polyamines attenuates angiotensin II induced blood pressure rise in rats. Clin Exp Hypertens. 18:811-830.
  • Pickkers P; Garcha R; Schachter M; Hughes AD. (1 Jul 1996). Action of thiazides and inhibitors of carbonic anhydrase on tone of guinea-pig isolated small mesenteric arteries. BRITISH JOURNAL OF PHARMACOLOGY. 118:P16-P16. Author weblink.
  • Pickkers P; Schachter M; Hughes AD; Feher MD; Sever PS. (Jul 1996). Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?. Diabetologia. 39:861-864.
  • Ibrahim J; Hughes AD; Schachter M; Sever PS. (May 1996). Enhanced tissue polyamine content in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol. 23:410-414.
  • Patel MK; Betteridge LJ; Hughes AD; Clunn GF; Schachter M; Shaw RJ; Sever PS. (Mar 1996). Effect of angiotension II on the expression of the early growth response gene c-fos and DNA synthesis in human vascular smooth muscle cells. J Hypertens. 14:341-347.
  • Clunn GF; Refson JS; Schachter M; Hughes AD. (Nov 1995). Different effects of platelet derived growth factor isoforms on DNA synthesis and migration in human vascular smooth muscle cells. Biochem Soc Trans. 23:608S.
  • Schachter M; Betteridge LJ; Hughes AD; Patel MK. (Aug 1995). Angiotensin II receptors are exclusively of the AT1 subtype in cultured human vascular smooth muscle cells. Biochem Soc Trans. 23:458S.
  • Pickkers P; Schachter M; Sever PS; Hughes AD. (Aug 1995). Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia?. J Hum Hypertens. 9:691-693.
  • Schachter M. (Aug 1995). New ideas for treating hypertension. J Hum Hypertens. 9:663-667.
  • Hughes AD; Schachter M. (May 1995). AIF4- inhibits influx of Ca2+ into vascular smooth muscle cells. Biochem Soc Trans. 23:171S.
  • Clunn GF; Schachter M; Hughes AD. (May 1995). Contrasting mechanisms of intracellular calcium ([Ca2+]i) elevation by angiotensin II (AII) and platelet derived growth factor-BB (PDGF-BB) in human vascular smooth muscle cells (VSMCs). Biochem Soc Trans. 23:170S.
  • Refson JS; Schachter M; Patel MK; Chan P; Wolfe JH; Sever P. (May 1995). Correlation of heparin binding with responsiveness in human vascular smooth muscle cells. Biochem Soc Trans. 23:172S.
  • Refson JS; Schachter M; Patel MK; Wolfe JH; Sever P. (May 1995). Differential mitogenic effects of PDGF isoforms and heparin on human vascular smooth muscle cells. Biochem Soc Trans. 23:173S.
  • Patel MK; Chan P; Betteridge LJ; Schachter M; Sever PS. (Apr 1995). Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol. 25:652-657.
  • Hughes AD; Patel M; Wijetunge S; Clunn G; Schachter M. (Mar 1995). Comparison of effects of platelet-derived growth factor isoforms on signaling and DNA synthesis of human cultured saphenous vein cells. J Cardiovasc Pharmacol. 25:481-485.
  • Ibrahim J; Schachter M; Hughes AD; Sever PS. (Jan 1995). Role of polyamines in hypertension induced by angiotensin II. Cardiovasc Res. 29:50-56.
  • Munro E; Patel M; Chan P; Betteridge L; Clunn G; Gallagher K; Hughes A; Schachter M; et alWolfe J; Sever P. (Nov 1994). Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest. 24:766-772.
  • Munro E; Chan P; Patel M; Betteridge L; Gallagher K; Schachter M; Sever P; Wolfe J. (Sep 1994). Consistent responses of the human vascular smooth muscle cell in culture: implications for restenosis. J Vasc Surg. 20:482-487.
  • Hughes AD; Clunn GF; Schachter M. (Aug 1994). A comparison of calcium channel currents in vascular smooth muscle cells from Watanabe hereditary hypercholesterolaemic and New Zealand white rabbits. Biochem Soc Trans. 22:361S.
  • Calder JA; Schachter M; Sever PS. (Jul 1994). Potassium channel opening properties of thiazide diuretics in isolated guinea pig resistance arteries. J Cardiovasc Pharmacol. 24:158-164.
  • Munro E; Patel M; Chan P; Betteridge L; Gallagher K; Schachter M; Wolfe J; Sever P. (May 1994). Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J Cardiovasc Pharmacol. 23:779-784.
  • SCHACHTER M; SEVER PS; CALDER JA. (1 May 1994). EFFECT OF THIAZIDE-LIKE DRUGS ON CALCIUM HOMEOSTASIS IN CULTURED GUINEA-PIG VASCULAR SMOOTH-MUSCLE CELLS. BRITISH JOURNAL OF PHARMACOLOGY. 112:U98-U98. Author weblink.
  • Munro E; Patel M; Chan P; Betteridge L; Gallagher K; Schachter M; Wolfe J; Sever P. (May 1994). Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis. Cardiovasc Res. 28:615-620.
  • CALDER JA; SCHACHTER M; SEVER PS. (1 May 1994). INDAPAMIDE BINDING IN GUINEA-PIG VASCULAR SMOOTH-MUSCLE CELLS. BRITISH JOURNAL OF PHARMACOLOGY. 112:U216-U216. Author weblink.
  • Hughes AD; Clunn GF; Schachter M. (May 1994). Low density lipoprotein and calcium homeostasis in human vascular smooth muscle cells. Biochem Soc Trans. 22:145S.
  • Calder JA; Schachter M; Sever PS. (21 Apr 1994). Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine. Eur J Pharmacol. 256:185-191.
  • Hughes AD; Schachter M. (Apr 1994). Hypertension and blood vessels. Br Med Bull. 50:356-370.
  • Hughes AD; Schachter M. (Apr 1994). Multiple pathways for entry of calcium and other divalent cations in a vascular smooth muscle cell line (A7r5). Cell Calcium. 15:317-330.
  • CALDER JA; SCHACHTER M; SEVER PS. (1 Jan 1994). COMPARISON OF INDAPAMIDE, 5-OH INDAPAMIDE AND HYDROCHLOROTHIAZIDE IN ISOLATED SMALL VESSELS. BRITISH JOURNAL OF PHARMACOLOGY. 111:P247-P247. Author weblink.
  • SCHACHTER M; HUGHES AD. (1 Jan 1994). EFFECT OF PLATELET-DERIVED GROWTH-FACTOR ISOFORMS ON INTRACELLULAR CA2+ IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS. BRITISH JOURNAL OF PHARMACOLOGY. 111:P306-P306. Author weblink.
  • Gillespie J; Dye JF; Schachter M; Guillou PJ. (Dec 1993). Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Br J Cancer. 68:1122-1126.
  • Calder JA; Schachter M; Sever PS. (Jun 1993). Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds. J Pharmacol Exp Ther. 265:1175-1180.
  • Gallagher DL; Betteridge LJ; Patel MK; Schachter M. (May 1993). Effect of oxidants on vascular smooth muscle proliferation. Biochem Soc Trans. 21:98S.
  • CALDER JA; SCHACHTER M; SEVER PS. (1 Apr 1993). INTERACTIONS BETWEEN THIAZIDE DIURETICS AND CYCLIC-NUCLEOTIDES IN ISOLATED SMALL ARTERIES. BRITISH JOURNAL OF PHARMACOLOGY. 108:P154-P154. Author weblink.
  • Chan P; Munro E; Patel M; Betteridge L; Schachter M; Sever P; Wolfe J. (Mar 1993). Cellular biology of human intimal hyperplastic stenosis. Eur J Vasc Surg. 7:129-135.
  • Chan P; Patel M; Betteridge L; Munro E; Schachter M; Wolfe J; Sever P. (6 Feb 1993). Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet. 341:341-342.
  • Wijetunge S; Aalkjaer C; Schachter M; Hughes AD. (30 Dec 1992). Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun. 189:1620-1623.
  • CALDER JA; SCHACHTER M; SEVER PS. (1 Dec 1992). IDENTIFICATION OF INDAPAMIDE BINDING-SITES IN GUINEA-PIG RENAL MEMBRANES. BRITISH JOURNAL OF PHARMACOLOGY. 107:P426-P426. Author weblink.
  • Calder JA; Schachter M; Sever PS. (10 Sep 1992). Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol. 220:19-26.
  • Gillespie J; Poston GJ; Schachter M; Guillou PJ. (Sep 1992). Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer. 66:483-487.
  • Calder JA; Schachter M; Sever PS. (Jul 1992). Interaction between cicletanine and the eicosanoid system in human subcutaneous resistance arteries. J Pharm Pharmacol. 44:574-578.
  • Calder JA; Schachter M; Sever PS. (Mar 1992). Mechanisms of action of cicletanine in human and guinea pig resistance arteries. J Cardiovasc Pharmacol. 19:387-393.
  • THOM S; HUGHES A; SCHACHTER M; SEVER P. (25 Jan 1992). CELIPROLOL. LANCET. 339:247-247. Author weblink DOI.
  • Garcha R; Schachter M; Hughes A; Thom SM; Sever P. (Dec 1991). Amlodipine inhibition of alpha-agonist induced contraction in human resistance vessels. J Hypertens Suppl. 9:S368-S369.
  • Schachter M. (Jul 1991). Drug-induced modification of vascular structure: effects of antihypertensive drugs. Am Heart J. 122:316-323.
  • Schachter M. (Apr 1991). Isradipine. J Clin Pharm Ther. 16:79-91.
  • Schachter M; Gallagher KL; Sever PS. (Dec 1990). Intracellular free magnesium in a vascular smooth muscle cell line. Biochem Soc Trans. 18:1266.
  • Schachter M; Gallagher KL; Sever PS. (Dec 1990). Intracellular glutathione and cytosolic calcium responses. Biochem Soc Trans. 18:1185-1186.
  • Schachter M. (Oct 1990). Endothelium and smooth muscle: trophic interactions and potential for therapeutic intervention. J Hum Hypertens. 4 Suppl 4:17-20.
  • Schachter M; Gallagher KL; Sever PS. (14 Sep 1990). Measurement of intracellular magnesium in a vascular smooth muscle cell line using a fluorescent probe. Biochim Biophys Acta. 1035:378-380.
  • Schachter M; Gallagher KL; Patel MK; Sever PS. (Dec 1989). Oxidants and vascular smooth muscle. Biochem Soc Trans. 17:1096-1097.
  • Schachter M. (Sep 1989). Recent advances in receptor research. Postgrad Med J. 65:613-621.
  • Hughes AD; Thom SA; Woodall N; Schachter M; Hair WM; Martin GN; Sever PS. (1989). Human vascular responses to endothelin-1: observations in vivo and in vitro. J Cardiovasc Pharmacol. 13 Suppl 5:S225-S228.
  • Hughes AD; Thom SA; Martin GN; Nielsen H; Hair WM; Schachter M; Sever PS. (Dec 1988). Size and site-dependent heterogeneity of human vascular responses in vitro. J Hypertens Suppl. 6:S173-S175.
  • Schachter M. (Jul 1988). Cyclosporine A and hypertension. J Hypertens. 6:511-516.
  • Schachter M. (Nov 1987). Do calcium antagonists affect platelets?. Eur Heart J. 8 Suppl K:75-82.
  • Schachter M; Miles CM; Leys K; Sever PS. (1987). Characterization of neuropeptide Y receptors in rabbit kidney: preliminary comparisons with rat and human kidney. J Cardiovasc Pharmacol. 10 Suppl 12:S157-S162.
  • PRICE LA; HILL BT; CALVERT AH; DALLEY M; LEVENE A; BUSBY ER; SCHACHTER M; SHAW HJ. (1 Jan 1978). IMPROVED RESULTS IN COMBINATION CHEMOTHERAPY OF HEAD AND NECK CANCER USING A KINETICALLY-BASED APPROACH - RANDOMIZED STUDY WITH AND WITHOUT ADRIAMYCIN. ONCOLOGY. 35:26-28. Author weblink.

Books

  • Schachter M. Combination Therapy and Hypertension. Taylor & Francis, London (2001).
  • Schachter M; Monkman D. Hypertension. 1-134. Elsevier Churchill Livingstone, Edinburgh (2004).

Chapters in books

  • Schachter M. Drugs affecting autonomic functions of the extrapyramidal system. In Side effects of drugs annual 25. 166-174. (2002).
  • Schachter M. Drugs affecting autonomic functions or the extrapyramidal system. In Side effects of drugs annual. 166-174. Aronson JK (ed). Elsevier, Amsterdam (2002).
  • Schachter M. Autonomic functions or the extrapyramidal system. In Side effects of drugs annual. 156-167. Aronson JK (ed). Elsevier, Amsterdam (2003).
  • Schachter M. New approaches in the treatment of hypertension. In New frontiers in hypertension. 101-113. Kaplan N (ed); Schachter M (ed). Lippincott Williams and Wilkins, London (2002).
  • Schachter M. Vascular biology of hypertension. In An Introduction to vascular biology. BJ (ed); Hunt (ed); Poston L (ed); Schachter M (ed); Halliday AW (ed). Cambridge University Press, Cambridge (2002).

Conferences

  • Hughes AD; Betteridge L; Clunn G; Patel M; Schachter M; Wijetunge S. Signals evoked by angiotensin II in vascular smooth muscle cells. International Workshop on Adrenal Glands, Vascular System and Hypertension, 20 Apr 1995 - 22 Apr 1995. 89-102. SOCIETY ENDOCRINOLOGY (1 Jan 1996). Author weblink.
  • Oakland KA; Schachter M; Hughes AD. Comparison of the effects of cysteine and homocysteine on endothelial progenitor cells in vitro. 12th Annual Meeting of the European-Council-for-Cardiovascular-Research, 12 Oct 2007 - 14 Oct 2007. 50:811-811. LIPPINCOTT WILLIAMS & WILKINS (1 Oct 2007). Author weblink.
  • HUGHES AD; CLUNN GF; SCHACHTER M. A COMPARISON OF CALCIUM-CHANNEL CURRENTS IN VASCULAR SMOOTH-MUSCLE CELLS FROM WATANABE HEREDITARY HYPERCHOLESTEROLEMIC AND NEW-ZEALAND WHITE-RABBITS. 650th Meeting of the Biochemical-Society. 22:S361-S361. (Aug 1994).
  • HUGHES AD; SCHACHTER M. AlF4- inhibits influx of Ca2+ into vascular smooth muscle cells. 653rd Meeting of the Biochemical-Society-of-London. 23:S171-S171. (May 1995).
  • CLUNN GF; SCHACHTER M; HUGHES AD. Contrasting mechanisms of intracellular calcium ([Ca2+](i)) elevation by angiotensin II (AII) and platelet derived growth Factor-BB (PDGF-BB) in human vascular smooth muscle cells (VSMCs). 653rd Meeting of the Biochemical-Society-of-London. 23:S170-S170. (May 1995).
  • Clunn GF; Refson JS; Schachter M; Hughes AD. Different effects of platelet derived growth factor isoforms on DNA synthesis and migration in human vascular smooth muscle cells. 655th Meeting of the Biochemical-Society. 23:S608-S608. (Nov 1995).
  • Schachter M. Secondary prevention: pharmacology. Symposium on Key Advances in the Effective Management of Myocardial Infarction. 39-44. (1999).
  • Packianathan S; Schachter M; Gallagher KL; Hughes AD. The effect of statins on vascular endothelial growth factor in human endothelial progenitor cells. 9th Annual Meeting of the European Council for Cardiovascular Research, 1 Oct 2004 - 3 Oct 2004. 44:587-587. LIPPINCOTT WILLIAMS & WILKINS (1 Oct 2004). Author weblink.
  • HUGHES AD; SCHACHTER M. ALF4- INHIBITS INFLUX OF CA2+ INTO VASCULAR SMOOTH-MUSCLE CELLS. 653rd Meeting of the Biochemical-Society-of-London, 13 Sep 1994 - 16 Sep 1994. 23:S171-S171. PORTLAND PRESS (1 May 1995). Author weblink.
  • CLUNN GF; SCHACHTER M; HUGHES AD. CONTRASTING MECHANISMS OF INTRACELLULAR CALCIUM ([CA2+](I)) ELEVATION BY ANGIOTENSIN-II (AII) AND PLATELET-DERIVED GROWTH FACTOR-BB (PDGF-BB) IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS (VSMCS). 653rd Meeting of the Biochemical-Society-of-London, 13 Sep 1994 - 16 Sep 1994. 23:S170-S170. PORTLAND PRESS (1 May 1995). Author weblink.
  • HUGHES AD; CLUNN GF; SCHACHTER M. LOW-DENSITY-LIPOPROTEIN AND CALCIUM HOMEOSTASIS IN HUMAN VASCULAR SMOOTH-MUSCLE CELLS. 649th Meeting of the Biochemical-Society, 19 Dec 1993 - 21 Dec 1993. 22:S145-S145. PORTLAND PRESS (1 May 1994). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook